This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
Avatar

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Ola Landgren
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Ola Landgren
261 views
June 12, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
12:49
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options…

Feat. P. Johnson
19:14
2024 ASCO® Annual Meeting Insights Hub

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

Feat. K. Rogers, J. Woyach
View All

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
28:20
Indy Hematology Review

Managing Newly Diagnosed MM in 2024

Feat. S. Usmani
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
06:19
Insights from 2023 ASH Annual Meeting

Dara-KRd in NDMM Without ASCT: Final Analysis of a Ph2 Trial

Feat. B. Derman
35:37
University of Colorado Division of Hematology

2024 Updates on Multiple Myeloma Treatment

Feat. D. Sherbenou
13:47
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…

Feat. B. Derman
11:38
Heinz Ludwig

Maintenance Therapy in Myeloma: Which Agent and for How Long?

16:28
Total Health

Multiple Myeloma: A New Risk-Adapted Approach

Feat. J. Chandler
11:02
Winship Cancer Institute - Emory University

Multiple Myeloma: Clinical Challenges for the Community Clinician

Feat. N. Joseph
15:36
Memorial Sloan Kettering Cancer Center

Key Myeloma & MGUS Updates From ASH

Feat. S. Mailankody
12:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…

Feat. C. Cerchione
05:47
Meletios Dimopoulos

PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Pa…

08:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Standard- and High-Risk ND Transplant-Eligi…

Feat. N. Joseph